| Objective To study the changes in bone mineral density, bone biochemistry and turnover markers in elderly patients with chronic obstructive pulmonary disease (COPD) and osteoporosis before and after treated with zoledronic acid and calcium. Methods 102 patients with COPD and osteoporosis were divided into treatment group (n=51) and control group (n=51) according to random number table. The control group was treated with calcium and the treatment group was treated with zoledronic acid in combination with calcium for 12 months. After treatment, the bone mineral density of lumbar vertebrae 1-4 (L1-4), femoral neck, and the levels of blood calcium (Ca), blood phosphorus (P), 25-hydroxyvitamin D [25(OH)D3], parathyroid hormone (PTH), osteocalcin (BGP), type 1 collagen carboxy terminal peptide (β-CTX) , Type 1 procollagen amino terminal peptide (P1NP) and bone alkaline phosphatase (BALP) were measured in the two groups. The adverse effects in the two groups of patients were recorded. Results After 12 months of treatment, the lumbar vertebrae 1-4 (L1-4) and femoral neck bone mineral density of the treatment group were significantly higher than those in the control group (P<0.05). In the treatment group, after 12 months of treatment, levels of serum PTH, BGP, P1NP and BALP were significantly higher than those before treatment (P<0.05), levels of 25(OH)D3 and β-CTX were significantly lower than those before treatment (P<0.05), and levels of blood calcium and phosphorus did not change significantly. There were no significant differences in the incidence of adverse drug reactions between the two groups (P>0.05). Conclusion Zoledronic acid combined with calcium could improve bone mineral density in elderly patients with COPD and osteoporosis, and improve bone biochemical and metabolic status. |